PRAX$320.39
$314.27
Chart
Performance
Key Stats
AI PRAX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldPraxis Precision Medicines (PRAX) shows promising therapeutic development in CNS disorders. Fundamentally, it's a clinical-stage company with significant cash burn and negative earnings, typical for its sector. Technicals indicate a mixed picture with recent price appreciation but also volatility. Thematic alignment with biotech innovation is strong, but execution risk and market sentiment are key factors.
Thematic
Praxis Precision Medicines is well-aligned with the growing demand for novel treatments in central nervous system (CNS) disorders. The company's focus on precision medicine and addressing unmet needs in conditions like essential tremor and epilepsy places it within a high-growth, innovation-driven thematic area.
Fundamental
As a clinical-stage biopharmaceutical company, Praxis Precision Medicines exhibits characteristics of high investment and negative profitability, typical for its industry. While it holds substantial cash reserves, its revenue generation is minimal, and it consistently reports significant net losses.
Technical
PRAX has experienced significant price appreciation over the past year, but recent momentum indicators suggest it may be approaching overbought territory. The stock is trading above key moving averages, indicating an overall bullish trend, but caution is warranted for short-term entry points.
| Factor | Score |
|---|---|
| Biotechnology Innovation | 85 |
| Precision Medicine & Personalized Healthcare | 80 |
| Healthcare Sector Growth | 70 |
| Regulatory Landscape (Biotech) | 60 |
| Strategic Partnerships | 70 |
| Factor | Score |
|---|---|
| Valuation | 20 |
| Profitability | 5 |
| Growth | 40 |
| Balance Sheet Health | 70 |
| Cash Flow | 15 |
| Debt Level | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 50 |
| Momentum | 45 |
| Moving Averages | 70 |
| Volume | 65 |
| Price Range | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Short-Term Performance
The stock has shown strong performance over the last 1 and 6 months, with a 5-day performance of 5.16% and a 1-month performance of 31.71%.
Potential Growth at Reasonable Price
While not explicitly stated, the company's reported revenue and net income figures (e.g., TTM Revenue of $7.765M, TTM Net Income of -$179.885M) coupled with a growing market cap (currently $1.18B) and positive stock performance may indicate future growth potential that could justify current or future valuations if profitability improves.
Bearish Points (8)
Consistent Net Losses
The company has consistently reported significant net losses (e.g., TTM Net Income of -$179.885M, 2024 Net Income of -$182.819M), with negative net margins indicating a lack of profitability.
Minimal Revenue
Reported revenues are very low ($7.765M TTM, $8.553M for 2024), suggesting the company is in early-stage development and has not yet established significant commercial operations.
Calendar
August 2025
11
Next Earnings Date
H: $-2.93
A: $-3.36
L: $-3.96
H: 1.00M
A: 157.13K
0Profile
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050. In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
Seasonals
Price Target
99.17 USD
The 39 analysts offering 1 year price forecasts for PRAX have a max estimate of 270.00 and a min estimate of 28.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Praxair merged with Linde AG to form Linde plc in 2018, making it the direct successor and most relevant entity in the industrial gas industry.
Weight: 95
A direct and primary global competitor to the former Praxair, specializing in the production and distribution of industrial and medical gases.
Weight: 90
A major global competitor to the former Praxair, providing industrial gases, equipment, and services across various industries.
Weight: 88
A significant global player in the industrial gas market, competing with the former Praxair, particularly strong in Asia.